FIELD: medicine.
SUBSTANCE: genetically engineered technique is applied to produce in Escherichia coli cells the recombinant polypeptides with human plasminogen properties containing a catalytic plasminogen domain, 5th and 4th plasminogen kringle domains, and a modified fragment of an amino acid sequence preceding to 4 plasminogen kringle domains.
EFFECT: invention allows producing the polypeptides of high fibrinolytic human plaminogen activity and yield 40-60 mg per 1 l of the culture in expression in Escherichia coli cells.
7 cl, 1 dwg, 3 ex
Authors
Dates
2011-10-27—Published
2009-11-24—Filed